Home › Biotech Rival to Teva's Blockbuster Said to Seek $40 Million IPO
 

Keywords :   


Biotech Rival to Teva's Blockbuster Said to Seek $40 Million IPO

2014-03-24 02:04:10| Biotech - Topix.net

Mapi Pharma Group, which is developing a longer acting version of Teva's blockbuster Copaxone drug, is considering selling shares in the U.S., a person with knowledge of the matter said.

Tags: million seek ipo biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05Eastern North Pacific Tropical Weather Outlook
16.05Atlantic Tropical Weather Outlook
16.05The man who turned his dead father into a chatbot
16.05Firms leaving UK 'not a crisis' says stock market boss
15.05Exploring the future of agriculture
15.05American, Mexican, and Canadian cattle producers sign joint statement
15.05Attitudes EWG Verified Skincare Line Oceanly Expands with SPF Offerings
15.05Sherwin-Williams Packaging Coatings Expands Non-BPA Coatings Production in Europe
More »